Accuri Cytometers

Press Releases

ACCURI CYTOMETERS INC. TO DISTRIBUTE FCS EXPRESS

Ann Arbor, MI - June 27, 2008

De Novo Software, a leading provider of flow cytometry data analysis solutions, and Accuri Cytometers, a privately held manufacturer of innovative benchtop flow cytometry systems, announced today that they have entered into a licensing agreement providing for Accuri to distribute a customized version of De Novo Software's flagship product, FCS Express, with every Accuri C6 Flow Cytometer System. Under the terms of the agreement, Accuri will distribute a time-limited Professional Version of FCS Express that includes the CFlow Importer. The customized version will provide Accuri customers with all of the functionality of the FCS Express Pro software for four months after purchase, at which time they will have the opportunity to purchase the software for continued use.

David Novo, De Novo Software's president said: "The Accuri C6 Flow Cytometer is one of the most innovative things to happen in the flow cytometry market in a long time. The System's combination of power and simplicity at an affordable price should help make C6 a formidable competitor and bring flow cytometry to many new users. Having Accuri distribute our software will expose FCS Express to a wide customer base. The seamless integration between the Accuri CFlow software and FCS Express, via the CFlow Importer, will be of great benefit to C6 users and we anticipate that many will wish to purchase the Professional version of the software after the initial trial period has expired."

"Offering FCS Express with the C6 Flow Cytometer provides Accuri's customers with a comprehensive analysis package that is seamlessly integrated with Accuri CFlow Software." said Jack Ball, Accuri's Chief Commercial Officer. "FCS Express will also enable our customers to analyze data from their Accuri CFlow software and from other flow cytometer platforms in one program, a useful convenience."

FCS Express has been adapted to read the individual data files inside the custom CFlow data files from the C6 Flow Cytometer as if they were individual FCS files, making file manipulation easy for C6 users. Since FCS Express works in a similar manner to commonly used software packages, such as the MS Office suite, it is consistent with Accuri's philosophy of providing simple, yet sophisticated, turnkey software solutions for its customers.

Press Release PDF file

ACCURI CYTOMETERS ANNOUNCES COMMERCIAL LAUNCH OF REVOLUTIONARY ACCURI C6 FLOW CYTOMETER™ SYSTEM

Ann Arbor, MI - April 7, 2008
Accuri Cytometers, Inc. today announced the commercial launch of the Accuri C6 Flow Cytometer™ System, designed to bring the power of flow cytometry cell analysis to the laboratory of every life sciences researcher. The Accuri C6 is a bench-top system that delivers performance and features similar to those of the market-leading flow cytometers, yet it is easy even for novice users to set up and operate. The radical redesign that produced the Accuri C6 has also made possible a dramatic reduction in price -- with the system selling for a fraction of the cost of most flow cytometers.

"The commercial availability of the Accuri C6 Flow Cytometer System is potentially transformative, since researchers increasingly rely on data that only flow cytometry can provide, yet most scientists currently lack routine access to this technology," said Dr. Larry A. Sklar, professor of pathology at the University of New Mexico Medical School and head of the National Institutes of Health-funded Molecular Libraries Screening Center. "The availability of easy--to-use, high-quality flow cytometers at the researcher's bench should enable far greater use of flow cytometry, resulting in many new applications for biomedical research."

The Accuri C6 Flow Cytometer System is a full-featured, two-laser, six-detector analytical system that includes the C6 Flow Cytometer, CFlow Software and a PC. The C6 Flow Cytometer System has detectors to capture both forward and side-scattered light, as well as four fluorescent detectors equipped with user-replaceable optical filters. The operating software is designed to make data collection and analysis fast and hassle-free.

"Our goal in creating the Accuri C6 System was to produce a high-performance cell analysis system that could bring the power of flow cytometry into the labs of life sciences researchers everywhere," said Jennifer Baird, CEO of Accuri. "We believe that the system we are commercially launching today achieves that ambitious goal. Developed by an interdisciplinary team with no pre-conceived ideas about flow cytometry, the C6 combines novel technology and software with simplicity of design and high-quality components to achieve performance similar to the leading flow cytometers, but with true ease-of-use, a bench-top footprint and a price affordable by virtually any laboratory." Accuri completely redesigned the hardware, user interface and analysis software of the C6 system with input from both researchers who use flow cytometry on a regular basis and those whose use have been limited by lack of access. The company teamed with Ann Arbor-based software firm Menlo Innovations, which brought its unique, award-winning methods to the development of the Accuri system's easy-to-use analysis software, a critical component of the approach. Accuri's innovations, coupled with its state of the art components, result in a cytometer that is powerful, robust, compact and affordable. The C6 Flow Cytometer works with all existing reagents and protocols, making the transition from current flow cytometers seamless.

"As a biomedical scientist I am acutely aware of how important flow cytometry is for my lab's research, yet the wait for access to a flow cytometer was often a major bottleneck to our progress," said Dr. Peter Smith, a researcher at Innovative BioTherapies, a biotechnology company developing a wearable artificial kidney. "I was therefore eager to serve as an early evaluator for the Accuri C6 Flow Cytometer System. Imagine my delight when, as a less experienced user, I was able to have the system running experiments within an hour of taking it out of the box. The hands-off simplicity and ease-of-use of the C6 system are liberating. The ability to conduct high-quality flow cytometry analyses simply and inexpensively whenever we need them will have a positive impact on the productivity of our lab."

Among the first major biomedical research institutions already using the Accuri C6 Flow Cytometer System are the University of California at San Francisco, Harvard University, the Medical University of South Carolina, the University of Michigan, the University of New Mexico and the University of Pittsburgh.

Accuri's chief commercial officer Jack Ball noted, "Initial response to the C6 Flow Cytometer System has been extremely encouraging, reflecting the pent-up demand for accessible, high-performance cell analysis tools in our initial target market--researchers currently using flow cytometers but frustrated by access limitations. Early access beta test users have been very positive, and every researcher we speak with reports that a flow cytometer that delivers on our performance specifications and is easy-to-use would find ready acceptance in their labs. With this formal market launch, we now look forward to fulfilling that demand."

Explicitly designed for routine use by biomedical researchers in their own labs, the Accuri C6 Flow Cytometer™ is a full featured bench-top cell and bead analysis system. For more information about Accuri and the C6 Flow Cytometer series, visit www.accuricytometers.com

Accuri C6 Full Featured Flow Cytometer System Features

Benefits

Come see how you can have Cell Analysis Within Reach™. Visit the Accuri booth at:

Press Release PDF file

ACCURI CYTOMETERS ADDS TWO HIGH PROFILE LIFE SCIENCES EXECUTIVES TO ITS BOARD OF DIRECTORS

Ann Arbor, MI - June 25, 2007
Accuri Cytometers, Inc., a life sciences company developing revolutionary bench-top flow cytometer systems, today announced the appointment of Daniel J. Calvo and George W. Dunbar to newly created positions on its Board of Directors.

"We are fortunate to have recruited these two outstanding individuals to our Board who are located in our own community," said Jennifer Baird, Chief Executive Officer of Accuri. "George and Dan have a wealth of successful strategic and operational experience in growing life sciences organizations and taking them to the next level, with expertise spanning early stage to global scale organizations. The fact that our region increasingly is home to senior executives of this caliber is a testament to the vitality of the Ann Arbor life sciences sector. Dan's and George's proximity to Accuri should enable us to benefit from their expertise on an ongoing basis as we continue our preparations for the commercial launch of our Accuri C6 Flow Cytometer™."

Press Release PDF file

ACCURI CYTOMETERS ANNOUNCES COMPLETION OF $5 MILLION SERIES B FINANCING LED BY BAIRD VENTURE PARTNERS

Ann Arbor, MI - April 16, 2007
Accuri Cytometers Inc., a life sciences company developing revolutionary bench-top flow cytometer systems, today announced the completion of a $5 million Series B financing led by Baird Venture Partners (BVP), the U.S.-based venture capital fund of Baird Private Equity. Arboretum Ventures of Ann Arbor co-led the financing. Both firms are new investors in Accuri, which intends to use the Series B proceeds for the ongoing testing and upcoming commercial launch of the Accuri C6 Flow Cytometer™ System. Pete Shagory of BVP and Tim Petersen of Arboretum will join the company's Board of Directors.

Series B Press Release PDF file